SCHEMBL21363437

SCHEMBL21363437

Cc1nc(N2CCOCC2)n2ncn(C)c(=O)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.43
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
HSD17B10 Q99714 1/20 0.39
DPP4 P27487 1/20 0.37
SYK P43405 3/20 0.37
TRPA1 O75762 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
STAT3 P40763 1/20 0.36
KMT2A Q03164 1/20 0.35
BRD4 O60885 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
CREBBP Q92793 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21363653 0.83 HTT (0.38) HTTUSP2ALDH1A1CYP1A2HSD17B10
SCHEMBL21363501 0.81 HTT (0.36) HTTUSP2ALDH1A1CYP1A2HSD17B10
Hydrochloric Acid SCHEMBL18742181 0.78 LMNA (0.38) HTTALDH1A1DPP4TRPA1KMT2A
SCHEMBL26155915 0.76 KMT2A (0.39) HTTUSP2ALDH1A1CYP1A2HSD17B10
SCHEMBL21363495 0.71 TRPA1 (0.41) USP2ALDH1A1CYP1A2HSD17B10TRPA1
SCHEMBL22477717 0.71 TRPA1 (0.41) USP2ALDH1A1CYP1A2HSD17B10TRPA1
SCHEMBL21363453 0.68 TRPA1 (0.42) USP2ALDH1A1CYP1A2HSD17B10DPP4
SCHEMBL22477716 0.68 TRPA1 (0.49) ALDH1A1CYP1A2HSD17B10DPP4TRPA1
SCHEMBL21363776 0.66 TRPA1 (0.41) USP2ALDH1A1CYP1A2HSD17B10DPP4
SCHEMBL21363544 0.66 TRPA1 (0.42) USP2ALDH1A1CYP1A2HSD17B10DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 HTT 1243/4885USP2 4614/4885ALDH1A1 721/4885
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 HTT 1243/4885USP2 4614/4885ALDH1A1 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.